vs
滨特尔（PNR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
滨特尔的季度营收约是Revvity的1.3倍（$1.0B vs $772.1M），滨特尔净利率更高（16.6% vs 12.7%，领先3.9%），Revvity同比增速更快（5.9% vs 2.6%），Revvity自由现金流更多（$161.8M vs $-85.7M），过去两年Revvity的营收复合增速更高（9.0% vs -2.9%）
滨特尔（股票代码PNR）是知名水处理企业，注册地位于爱尔兰，税务居民身份归属英国，美国区总部设于明尼苏达州金谷市。品牌起源于美国，2017年数据显示其65%的营收来自美国和加拿大，2014年集团完成架构重组，注册地由瑞士变更为爱尔兰。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
PNR vs RVTY — 直观对比
营收规模更大
PNR
是对方的1.3倍
$772.1M
营收增速更快
RVTY
高出3.2%
2.6%
净利率更高
PNR
高出3.9%
12.7%
自由现金流更多
RVTY
多$247.5M
$-85.7M
两年增速更快
RVTY
近两年复合增速
-2.9%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0B | $772.1M |
| 净利润 | $172.4M | $98.4M |
| 毛利率 | 41.8% | — |
| 营业利润率 | 20.3% | 14.5% |
| 净利率 | 16.6% | 12.7% |
| 营收同比 | 2.6% | 5.9% |
| 净利润同比 | 11.3% | 3.9% |
| 每股收益（稀释后） | — | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PNRRVTY
| Q1 26 | $1.0B | — | ||
| Q4 25 | $1.0B | $772.1M | ||
| Q3 25 | $1.0B | $698.9M | ||
| Q2 25 | $1.1B | $720.3M | ||
| Q1 25 | $1.0B | $664.8M | ||
| Q4 24 | $972.9M | $729.4M | ||
| Q3 24 | $993.4M | $684.0M | ||
| Q2 24 | $1.1B | $691.7M |
净利润PNRRVTY
| Q1 26 | $172.4M | — | ||
| Q4 25 | $166.1M | $98.4M | ||
| Q3 25 | $184.3M | $46.7M | ||
| Q2 25 | $148.5M | $53.9M | ||
| Q1 25 | $154.9M | $42.2M | ||
| Q4 24 | $166.4M | $94.6M | ||
| Q3 24 | $139.6M | $94.4M | ||
| Q2 24 | $186.1M | $55.4M |
毛利率PNRRVTY
| Q1 26 | 41.8% | — | ||
| Q4 25 | 40.4% | — | ||
| Q3 25 | 41.0% | 53.6% | ||
| Q2 25 | 40.7% | 54.5% | ||
| Q1 25 | 39.9% | 56.5% | ||
| Q4 24 | 38.8% | — | ||
| Q3 24 | 39.6% | 56.3% | ||
| Q2 24 | 39.8% | 55.7% |
营业利润率PNRRVTY
| Q1 26 | 20.3% | — | ||
| Q4 25 | 20.1% | 14.5% | ||
| Q3 25 | 22.7% | 11.7% | ||
| Q2 25 | 19.4% | 12.6% | ||
| Q1 25 | 20.1% | 10.9% | ||
| Q4 24 | 20.1% | 16.3% | ||
| Q3 24 | 18.1% | 14.3% | ||
| Q2 24 | 22.6% | 12.4% |
净利率PNRRVTY
| Q1 26 | 16.6% | — | ||
| Q4 25 | 16.3% | 12.7% | ||
| Q3 25 | 18.0% | 6.7% | ||
| Q2 25 | 13.2% | 7.5% | ||
| Q1 25 | 15.3% | 6.4% | ||
| Q4 24 | 17.1% | 13.0% | ||
| Q3 24 | 14.1% | 13.8% | ||
| Q2 24 | 16.9% | 8.0% |
每股收益（稀释后）PNRRVTY
| Q1 26 | — | — | ||
| Q4 25 | $1.01 | $0.86 | ||
| Q3 25 | $1.12 | $0.40 | ||
| Q2 25 | $0.90 | $0.46 | ||
| Q1 25 | $0.93 | $0.35 | ||
| Q4 24 | $0.99 | $0.77 | ||
| Q3 24 | $0.84 | $0.77 | ||
| Q2 24 | $1.11 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $67.7M | $919.9M |
| 总债务越低越好 | $1.9B | — |
| 股东权益账面价值 | $3.8B | $7.3B |
| 总资产 | $7.1B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.51× | — |
8季度趋势，按日历期对齐
现金及短期投资PNRRVTY
| Q1 26 | $67.7M | — | ||
| Q4 25 | — | $919.9M | ||
| Q3 25 | $128.4M | $931.4M | ||
| Q2 25 | $143.0M | $991.8M | ||
| Q1 25 | $140.6M | $1.1B | ||
| Q4 24 | $118.7M | $1.2B | ||
| Q3 24 | $218.1M | $1.2B | ||
| Q2 24 | $214.3M | $2.0B |
总债务PNRRVTY
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.6B | — | ||
| Q2 25 | $1.4B | — | ||
| Q1 25 | $1.8B | — | ||
| Q4 24 | $1.6B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $1.8B | — |
股东权益PNRRVTY
| Q1 26 | $3.8B | — | ||
| Q4 25 | $3.9B | $7.3B | ||
| Q3 25 | $3.8B | $7.4B | ||
| Q2 25 | $3.7B | $7.6B | ||
| Q1 25 | $3.6B | $7.6B | ||
| Q4 24 | $3.6B | $7.7B | ||
| Q3 24 | $3.5B | $7.9B | ||
| Q2 24 | $3.4B | $7.9B |
总资产PNRRVTY
| Q1 26 | $7.1B | — | ||
| Q4 25 | $6.9B | $12.2B | ||
| Q3 25 | $6.8B | $12.1B | ||
| Q2 25 | $6.5B | $12.4B | ||
| Q1 25 | $6.7B | $12.4B | ||
| Q4 24 | $6.4B | $12.4B | ||
| Q3 24 | $6.5B | $12.8B | ||
| Q2 24 | $6.5B | $13.4B |
负债/权益比PNRRVTY
| Q1 26 | 0.51× | — | ||
| Q4 25 | 0.42× | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.51× | — | ||
| Q4 24 | 0.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.51× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-85.7M | $161.8M |
| 自由现金流率自由现金流/营收 | -8.3% | 21.0% |
| 资本支出强度资本支出/营收 | 1.8% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $716.0M | $509.4M |
8季度趋势，按日历期对齐
经营现金流PNRRVTY
| Q1 26 | — | — | ||
| Q4 25 | $50.8M | $182.0M | ||
| Q3 25 | $196.3M | $138.5M | ||
| Q2 25 | $606.6M | $134.3M | ||
| Q1 25 | $-38.9M | $128.2M | ||
| Q4 24 | $86.5M | $174.2M | ||
| Q3 24 | $248.6M | $147.9M | ||
| Q2 24 | $539.2M | $158.6M |
自由现金流PNRRVTY
| Q1 26 | $-85.7M | — | ||
| Q4 25 | $27.1M | $161.8M | ||
| Q3 25 | $178.9M | $120.0M | ||
| Q2 25 | $595.7M | $115.5M | ||
| Q1 25 | $-55.7M | $112.2M | ||
| Q4 24 | $63.8M | $149.8M | ||
| Q3 24 | $233.2M | $125.6M | ||
| Q2 24 | $522.2M | $136.6M |
自由现金流率PNRRVTY
| Q1 26 | -8.3% | — | ||
| Q4 25 | 2.7% | 21.0% | ||
| Q3 25 | 17.5% | 17.2% | ||
| Q2 25 | 53.0% | 16.0% | ||
| Q1 25 | -5.5% | 16.9% | ||
| Q4 24 | 6.6% | 20.5% | ||
| Q3 24 | 23.5% | 18.4% | ||
| Q2 24 | 47.5% | 19.7% |
资本支出强度PNRRVTY
| Q1 26 | 1.8% | — | ||
| Q4 25 | 2.3% | 2.6% | ||
| Q3 25 | 1.7% | 2.6% | ||
| Q2 25 | 1.0% | 2.6% | ||
| Q1 25 | 1.7% | 2.4% | ||
| Q4 24 | 2.3% | 3.4% | ||
| Q3 24 | 1.6% | 3.3% | ||
| Q2 24 | 1.5% | 3.2% |
现金转化率PNRRVTY
| Q1 26 | — | — | ||
| Q4 25 | 0.31× | 1.85× | ||
| Q3 25 | 1.07× | 2.97× | ||
| Q2 25 | 4.08× | 2.49× | ||
| Q1 25 | -0.25× | 3.03× | ||
| Q4 24 | 0.52× | 1.84× | ||
| Q3 24 | 1.78× | 1.57× | ||
| Q2 24 | 2.90× | 2.87× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PNR
| Water Solutions | $391.0M | 38% |
| Pool | $387.1M | 37% |
| Flow | $258.1M | 25% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
